BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BGC-0228’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BGC-0228 overview

BGC-0228 is under development for the treatment of solid tumors including breast cancer, metastatic pancreatic cancer, epithelial ovarian cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, small-cell lung cancer. It is a long-acting peptide-targeted conjugate drug (peptide-drug conjugate) administered through parenteral route in the form of powder. The drug candidate comprises of polymer conjugated with cytotoxic drug and is being developed based on targeted polymer coupling platform. It acts by targeting cells expressing CD44 antigen. 

BrightGene Bio-Medical Technology overview

BrightGene Bio-Medical Technology (BrightGene) is a biopharmaceutical company that manufactures, research and develop generic drugs. The company’s pipeline products include posaconazole, oseltamivir phosphate, orivancin, fidaxomycin, agatroban, fondaparinux, acarbose, iron supplements, trabectidine, pemetrexed disodium intermediate, eribulin mesylate, midotolin, everolimus and pimecrolimus, among others. Its veterinary drugs include seramectin, telavancin hydrochloride, emodes, doramectin and dalbavancin. The company develops products in the therapeutic areas of cardiology, oncology, antibacterial, antifungal and veterinary. BrightGene is headquartered in Suzhou, Jiangsu, China.

For a complete picture of BGC-0228’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.